High-Dose Naltrexone Therapy for Cocaine-Alcohol Dependence

REFERENCES

• Heil SH, Badger GJ, Higgins ST. Alcohol dependence among cocaine-dependent outpatients: demographics, drug use, treatment outcome and other characteristics. J Stud Alcohol. 2001;62:14–22.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Rounsaville BJ, Gordon LT, Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic significance. J Stud Alcohol. 1993;54:199–208.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Mirin SM, Griffin ML, Michael JL. Psychopathology in cocaine abusers. Changing trends. J Nerv Ment Dis. 1988;176:719–725.
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Bordnick PS, Kearney ML, Fuller SM, Breckenridge JK. Treatment outcome of cocaine-alcohol dependent patients. Drug Alcohol Depend. 1997;47:55–61.
   PubMed Web of Science ®Google Scholar
• Brady KT, Sonne S, Randall CL, Adinoff B, Malcolm R. Features of cocaine dependence with concurrent alcohol abuse. Drug Alcohol Depend. 1995;39:69–71.
   PubMed Web of Science ®Google Scholar
• Brower KJ, Blow FC, Hill EM, Mudd SA. Treatment outcome of alcoholics with and without cocaine disorders. Alcohol Clin Exp Res. 1994;18:734–739.
   PubMed Web of Science ®Google Scholar
• Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl). 1998;139:44–52.
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict. 2004;13:333–341.
   PubMed Web of Science ®Google Scholar
• McCaul ME. Efficacy of natrexone for alcoholics with and without comorbid opiate or cocaine dependence. Alcoholism: Clinical and experimental research. 1996;20:216A–218A.
   Google Scholar
• Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat. 1999;16:163–167.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, Kampman KM, Lynch KG, Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008;34:378–390.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Oliveto A, Feingold A, Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70:315–325.
   PubMed Web of Science ®Google Scholar
• Poling J, Oliveto A, Petry N, Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63:219–228.
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Rhoades HM, Elk R, Creson D, Hussein I, Grabowski J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol. 1998;6:162–168.
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008;94:142–150.
   PubMed Web of Science ®Google Scholar
• Sayre SL, Evans M, Hokanson PS, “Who gets in?” Recruitment and screening processes of outpatient substance abuse trials. Addict Behav. 2004;29:389–398.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders-patient edition (SCID -I / P, Version 2.0). 1995: Biometric Research Department, NY.
   Google Scholar
• Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl. 1994;12:70–75.
   PubMedGoogle Scholar
• Marlatt GA. Relapse prevention: theoretical rationale and overview of the model. In: Marlatt GA, Gordon JR, eds. Relapse prevention. New York, NY: Guilford Press; 1985:3–70.
   Google Scholar
• Schmitz JM, Oswald LM, Jacks SD, Rustin T, Rhoades HM, Grabowski J. Relapse prevention treatment for cocaine dependence: group vs. individual format. Addict Behav. 1997;22:405–418.
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26:167–180.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Higgins ST. A community reinforcement plus vouchers approach: Treating cocaine addiction. Therapy manuals for drug addiction. 1998, USDHHS NIH.
   Google Scholar
• McLellan AT, Kushner H, Metzger D, The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199–213.
   PubMed Web of Science ®Google Scholar
• Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20:1412–1417.
   PubMedGoogle Scholar
• Mooney ME, Sayre SL, Green C, Rhoades H, Schmitz JM. Comparing measures of medication taking in a pharmacotherapy trial for cocaine dependence. Addictive Disorders & Their Treatment. 2004;3:165–173.
   Google Scholar
• Ling W, Shoptaw S, Wesson D, Rawson RA, Compton M, Klett CJ. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr. 1997;175:208–220.
   PubMedGoogle Scholar
• Sanchez-Craig M, Wilkinson DA, Davila R. Empirically based guidelines for moderate drinking: 1-year results from three studies with problem drinkers. Am J Public Health. 1995;85:823–828.
   PubMed Web of Science ®Google Scholar
• SAS, The SAS System for Windows (Version 9.13). 2006, SAS Institute Inc.: Cary, NC.
   Google Scholar
• Pettinati HM, Kampman KM, Lynch KG, A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav. 2008;33:651–667.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Lynch KG, Pettinati HM, A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res. 2008;32:1299–1308.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kranzler HR, O'Malley SS, Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617–1625.
   PubMed Web of Science ®Google Scholar
• Smith JE, Meyers RJ, Miller WR. The community reinforcement approach to the treatment of substance use disorders. Am J Addict. 2001;10 Suppl: p. 51–59.
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry. 1995;152:613–615.
   PubMed Web of Science ®Google Scholar
• Grassi MC, Cioce AM, Giudici FD, Antonilli L, Nencini P. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacol Res. 2007;55:117–121.
   PubMed Web of Science ®Google Scholar
• Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101:192–203.
   PubMed Web of Science ®Google Scholar